[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112012030029A2 - beta-lactamases modificadas e métodos e usos relacionados a elas - Google Patents

beta-lactamases modificadas e métodos e usos relacionados a elas

Info

Publication number
BR112012030029A2
BR112012030029A2 BR112012030029A BR112012030029A BR112012030029A2 BR 112012030029 A2 BR112012030029 A2 BR 112012030029A2 BR 112012030029 A BR112012030029 A BR 112012030029A BR 112012030029 A BR112012030029 A BR 112012030029A BR 112012030029 A2 BR112012030029 A2 BR 112012030029A2
Authority
BR
Brazil
Prior art keywords
beta
lactamases
relates
lactamase
related methods
Prior art date
Application number
BR112012030029A
Other languages
English (en)
Other versions
BR112012030029B1 (pt
Inventor
Valimaki Katja
Koski Pertti
Airaksinen Ulla
Original Assignee
Prevabr Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prevabr Llc filed Critical Prevabr Llc
Publication of BR112012030029A2 publication Critical patent/BR112012030029A2/pt
Publication of BR112012030029B1 publication Critical patent/BR112012030029B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/86—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in cyclic amides, e.g. penicillinase (3.5.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/75—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/02—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amides (3.5.2)
    • C12Y305/02006—Beta-lactamase (3.5.2.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)

Abstract

beta-lactamases modificadas e métodos e usos relacionados a elas. a presente invenção refere-se a produtos farmacêuticos e beta-lactamases modificadas. especificamente, a invenção refere-se a novos recombinates beta-lactamases e composições farmacêuticas compreendendo as beta-lactamases. além disso, a presente invenção diz respeito a métodos para a modificação de uma beta-lactamase, produzindo a beta-lactamase e no tratamento ou prevenção de beta-lactâmica induzido por efeitos adversos. além disso, a presente invenção relaciona-se com a beta-lactamase para o uso como um medicamento e para o uso da beta-lactamase na fabricação de um medicamento para o tratamento ou prevenção de antibióticos beta-lactâmicos, induzido por efeitos adversos. ainda além disso, a invenção refere-se a um polinucleotídeo e de uma célula hospedeira compreendendo o polinucleotídeo.
BR112012030029-6A 2010-05-24 2011-05-17 Beta-lactamases modificadas, métodos, polinucleotídeo e composições relacionadas BR112012030029B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20105572 2010-05-24
FI20105572A FI20105572A0 (fi) 2010-05-24 2010-05-24 Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt
PCT/FI2011/050450 WO2011148041A1 (en) 2010-05-24 2011-05-17 Modified beta-lactamases and methods and uses related thereto

Publications (2)

Publication Number Publication Date
BR112012030029A2 true BR112012030029A2 (pt) 2017-05-02
BR112012030029B1 BR112012030029B1 (pt) 2021-08-17

Family

ID=42234353

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012030029-6A BR112012030029B1 (pt) 2010-05-24 2011-05-17 Beta-lactamases modificadas, métodos, polinucleotídeo e composições relacionadas

Country Status (17)

Country Link
US (11) US9034602B2 (pt)
EP (1) EP2576776B1 (pt)
JP (1) JP5827681B2 (pt)
KR (1) KR101708703B1 (pt)
CN (1) CN103038341B (pt)
AU (1) AU2011257092C1 (pt)
BR (1) BR112012030029B1 (pt)
CA (1) CA2800671C (pt)
DK (1) DK2576776T3 (pt)
ES (1) ES2588279T3 (pt)
FI (1) FI20105572A0 (pt)
HK (1) HK1183905A1 (pt)
HU (1) HUE030689T2 (pt)
PL (1) PL2576776T3 (pt)
RU (1) RU2570551C2 (pt)
WO (1) WO2011148041A1 (pt)
ZA (1) ZA201208948B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8992422B2 (en) 2006-03-23 2015-03-31 Ethicon Endo-Surgery, Inc. Robotically-controlled endoscopic accessory channel
FI20105572A0 (fi) 2010-05-24 2010-05-24 Prevab R Lcc Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt
AU2015247382B2 (en) 2014-04-17 2020-04-23 Theriva Biologics, Inc. Beta-lactamases with improved properties for therapy
CA2958755C (en) * 2014-08-28 2023-02-28 Synthetic Biologics, Inc. E. coli-based production of beta-lactamase
US10105322B2 (en) 2014-10-08 2018-10-23 Synthetic Biologics, Inc. Beta-lactamase formulations and uses thereof
FR3027307B1 (fr) * 2014-10-16 2016-11-04 Azurrx Sas Molecule proteique hybride apte a inhiber au moins un antibiotique et composition pharmaceutique la comportant
EP3236993B1 (en) * 2014-12-23 2023-09-13 Theriva Biologics, Inc. Methods and compositions for inhibiting or preventing adverse effects of oral antibiotics
AU2016222936B2 (en) 2015-02-23 2022-01-06 Theriva Biologics, Inc. Carbapenemases for use with antibiotics for the protection of the intestinal microbiome
CA2978604A1 (en) 2015-03-06 2016-09-15 Synthetic Biologics, Inc. Safe and effective beta-lactamase dosing for microbiome protection
US10982205B2 (en) * 2016-02-23 2021-04-20 Da Volterra Beta-lactamase variants
US11185555B2 (en) 2016-04-11 2021-11-30 Noah James Harrison Method to kill pathogenic microbes in a patient
US11517614B2 (en) 2016-06-28 2022-12-06 Synthetic Biologics, Inc. Microbiome protection from oral antibiotics
CN110062623A (zh) * 2016-11-01 2019-07-26 合成生物制品有限公司 用于减弱抗生素抗性的方法和组合物
CN110157699B (zh) * 2018-02-12 2021-07-23 中国科学院微生物研究所 β-内酰胺酶及其编码基因以及它们的应用
CA3106429A1 (en) 2018-08-05 2020-02-13 Da Volterra Method for improving anticancer agent efficacy
WO2020030593A1 (en) 2018-08-05 2020-02-13 Da Volterra Compositions for the treatment of graft versus host disease
CN110777178A (zh) * 2019-12-02 2020-02-11 河北慧林生物科技有限公司 固定化羧基酯水解酶在氯唑西林、双氯西林、氟氯西林及苯唑西林侧链合成中的应用
CN114075560A (zh) * 2020-08-18 2022-02-22 杭州俊丰生物工程有限公司 一种β-内酰胺酶的稳定组合物
EP4148136A1 (en) 2021-09-08 2023-03-15 Da Volterra An engineered yeast cell for the delivery of antibiotic-inactivating enzymes

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL89987C (pt) 1954-05-29
US2941995A (en) 1957-08-02 1960-06-21 Beecham Res Lab Recovery of solid 6-aminopenicillanic acid
US2982696A (en) 1959-05-01 1961-05-02 Schenley Ind Inc Ion-exchange procedures for the purification of penicillinase
US3070511A (en) 1960-02-10 1962-12-25 Lepetit Spa Process for preparing 6-aminopenicillanic acid
US3150059A (en) 1962-12-26 1964-09-22 Lilly Co Eli Penicillin deacylation via actinoplanaceae fermentation
US3239394A (en) 1964-06-15 1966-03-08 Merck & Co Inc Process for producing 7-amino-cephalosporanic acid
US3499909A (en) 1966-05-18 1970-03-10 Koninklijke Gist Spiritus Process for production of 6-aminopenicillanic acid
US3488729A (en) 1966-08-22 1970-01-06 Lilly Co Eli Cephalothin ester
GB1241844A (en) 1968-08-23 1971-08-04 Beecham Group Ltd Penicillins
FI59265C (fi) 1974-08-13 1981-07-10 Beecham Group Ltd Foerfarande foer framstaellning av 6-aminopenicillansyra
GB1463513A (en) 1974-08-13 1977-02-02 Beecham Group Ltd Enzymes
GB2199582A (en) 1987-01-07 1988-07-13 Bayer Ag Analogues of pancreatic secretory trypsin inhibitor
FR2613624B1 (fr) 1987-04-10 1990-11-23 Roussy Inst Gustave Composition pharmaceutique, administrable par voie orale, destinee a reduire les effets des b-lactamines
CA2007083A1 (en) 1989-01-09 1990-07-09 Nobuhiko Katunuma Pharmaceutical use of trypstatin
CS275231B2 (en) 1989-09-29 1992-02-19 Ustav Makormolekularni Chemie Medicine bottle
FI920206A0 (fi) 1992-01-17 1992-01-17 Pekka Untamo Heino Medicinsk anvaendning, medicinskt foerfarande och preparat.
EP0837925A1 (en) 1995-07-07 1998-04-29 Novo Nordisk A/S Production of proteins using bacillus incapable of sporulation
US7585674B2 (en) 2001-05-29 2009-09-08 Kao Corporation Host microorganisms
FI112666B (fi) 2001-11-06 2003-12-31 Ipsat Therapies Oy Itiöimätön Bacillus subtilis, sen valmistus ja käyttö
FR2843302B1 (fr) 2002-08-09 2004-10-22 Centre Nat Rech Scient Forme galenique pour la delivrance colique de principes actifs
US7323303B2 (en) * 2003-03-31 2008-01-29 Hong Kong Polytechnic University Modified β-lactamases and uses thereof
EP1564286A1 (en) * 2004-02-11 2005-08-17 Université de Liège Hybrid proteins of beta-lactamase class A
IL163821A0 (en) * 2004-08-31 2005-12-18 Ravgalai Ltd Rapax Consortium Software for management of legal motions Methods and kits for the detection of biotoxic andantibiotic residues
DK1883396T3 (da) 2005-05-18 2013-10-07 Centre Nat Rech Scient Afgivelse af adsorptionsmidler til tyktarmen
FI119190B (fi) * 2006-06-21 2008-08-29 Ipsat Therapies Oy Modifioitu beta-laktamaasi ja menetelmä sen valmistamiseksi
FI119678B (fi) 2006-11-28 2009-02-13 Ipsat Therapies Oy Beta-laktamaasin käyttö
FI20105572A0 (fi) 2010-05-24 2010-05-24 Prevab R Lcc Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt

Also Published As

Publication number Publication date
JP5827681B2 (ja) 2015-12-02
US9587234B2 (en) 2017-03-07
US20170145402A1 (en) 2017-05-25
US20230332128A1 (en) 2023-10-19
WO2011148041A1 (en) 2011-12-01
US20130216622A1 (en) 2013-08-22
EP2576776B1 (en) 2016-07-13
CN103038341A (zh) 2013-04-10
JP2013529905A (ja) 2013-07-25
EP2576776A1 (en) 2013-04-10
KR101708703B1 (ko) 2017-02-21
KR20130133648A (ko) 2013-12-09
US20220090044A1 (en) 2022-03-24
RU2012155420A (ru) 2014-06-27
US10041056B2 (en) 2018-08-07
PL2576776T3 (pl) 2017-01-31
US20160230160A1 (en) 2016-08-11
US20150056178A1 (en) 2015-02-26
US9301995B2 (en) 2016-04-05
US8894994B2 (en) 2014-11-25
HK1183905A1 (zh) 2014-01-10
DK2576776T3 (en) 2016-10-03
US9765320B2 (en) 2017-09-19
US20150209418A1 (en) 2015-07-30
AU2011257092C1 (en) 2014-06-19
ES2588279T3 (es) 2016-10-31
CA2800671A1 (en) 2011-12-01
HUE030689T2 (en) 2017-05-29
US9034602B2 (en) 2015-05-19
AU2011257092B2 (en) 2013-12-19
US20190169590A1 (en) 2019-06-06
US20140127785A1 (en) 2014-05-08
CA2800671C (en) 2018-09-18
AU2011257092A1 (en) 2013-01-10
US11214787B2 (en) 2022-01-04
RU2570551C2 (ru) 2015-12-10
BR112012030029B1 (pt) 2021-08-17
CN103038341B (zh) 2016-04-20
US10253306B2 (en) 2019-04-09
ZA201208948B (en) 2014-02-26
US20160168557A1 (en) 2016-06-16
US9301996B2 (en) 2016-04-05
EP2576776A4 (en) 2014-01-22
US20170327812A1 (en) 2017-11-16
FI20105572A0 (fi) 2010-05-24

Similar Documents

Publication Publication Date Title
BR112012030029A2 (pt) beta-lactamases modificadas e métodos e usos relacionados a elas
BR112019008431A2 (pt) aplicação de (s)-norcetamina e sal da mesma como fármaco
BR112015019720B8 (pt) Inibidores de (benzil-ciano-metil)-amidas de ácido 2-azabiciclo[2.2.1]heptano-3-carboxílico substituído da catepsina c e composição farmacêutica
PH12017501306A1 (en) Inhibitors of histone demethylases
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112017003433A2 (pt) inibidores espirocíclicos de catepsina c
PH12014501984A1 (en) Pharmaceutical compositions comprising metformin and a dpp-4 inhibitor or a sglt-2 inhibitor
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
EA201590053A1 (ru) Модуляторы пути системы комплемента и их применение
BR112013006344A2 (pt) lactamas substituídas por piperdinila como moduladores de gpr119, composição farmacêutica as compreendendo, uso e processso para preparação das mesmas
DOP2013000192A (es) Compuestos y composiciones como inhibidores de la trk
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
BR112012027034A2 (pt) inibidores da arginase e suas aplicações terapêuticas
BR112014008731A2 (pt) tratamento de esclerose múltipla com combinação de laquinimode e fingolimode
BR112015002152A2 (pt) pirróis substituídos ativos como inibidores de quinases
BR112014024672A8 (pt) Composições farmacêuticas para terapia de combinação
BRPI1015996B8 (pt) composição oftálmica de múltiplas doses contendo complexos de borato-poliol.
BR112017004741A2 (pt) compostos e composições como inibidores da raf quinase
BR112012021889A2 (pt) amida heteocíclicas como inibidores rock
BR112015019873A2 (pt) inibidores macrocíclicos da lrrk2 cinase
BR112015003729A8 (pt) Composto de fórmula estrutural i; composição farmacêutica; método de tratamento de uma doença mediada por caminho do hif; método de tratamento de uma doença causada por proliferação anormal de células; e método para alcançar um efeito em um paciente
BR112015030385A2 (pt) inibidores de pi3 delta e gama quinase seletivos duplos
BR112014027047A2 (pt) nova formulação
BR112016013754A2 (pt) Recaptação de serotonina-norepinefrina inibidores (irsns) e combinações dos ligantes do receptor sigma
BR112014010594A2 (pt) terapia genética para neuropatia diabética empregando um isoforma do hgf

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/05/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.